RFA-HL-26-002: NHLBI Outstanding Investigator Award (OIA) 2027 R35 for HLBS Research

Captured cycle: This page is retained for historical guidance. Confirm whether the program has reopened before planning an application.

RFA-HL-26-002: NHLBI Outstanding Investigator Award (OIA) 2027: Up to $700k/year for 7 Years

NHLBI’s RFA-HL-26-002 is the Outstanding Investigator Award (OIA) in the R35 model. It is designed for established heart, lung, blood, and sleep (HLBS) researchers who already run significant independent programs and want long-horizon, flexible support instead of short grant-specific deliverables.

This is a strong opportunity for a 2026/2027 filing because the NOFO keeps regular cycles and explicitly shows a 2027 full submission deadline. It is a high-signal program for investigators already on a stable research trajectory and willing to restructure their NHLBI portfolio into a coherent, multi-year OIA program.

Key details table

What this opportunity is really meant to do

Most grant programs are designed around a project with defined aims and milestones. OIA is not like that.

The program is explicitly intended to fund the research program of an investigator rather than a single project. In practical terms, this changes everything:

• It favors research leaders with a stable track record.
• It rewards strategic, high-risk thinking over rigid short-cycle deliverables.
• It expects a clear long-term scientific vision and institutional commitment.
• It can replace existing individual NHLBI project awards (except for some specified exclusions and compatible categories).

For teams that are early, this can be the wrong fit. For a mature investigator with proven continuity and substantial NHLBI support history, it is often one of the most leveraged funding opportunities in the cycle.

Why this still matters for the 2026–2027 cycle

The NOFO shows recurring NIH windows that include 2026 and 2027. That means this is useful not only for immediate FY2026 responses but also as a strategic target for the next cycle. Two facts in the announcement make this useful for 2027 planning:

• The program keeps explicit future due cycles, with a posted 2027 deadline and review-to-award sequence.
• The funding limits are high enough to support substantial sustained research teams when aligned with NHLBI mission priorities.

Even if your current project is not fully “finished,” the OIA model suits people who are at the stage where the research trajectory itself is the project. If your work has matured into a full program and you want to avoid fragmented grant writing every year, this NOFO is aligned with that need.

Eligibility: strict, explicit, and easy to fail if misunderstood

The NOFO is very specific. This is one of the most common reasons applicants fail before science is even reviewed.

Applicant-level requirements

The NOFO limits eligibility to proven, senior-level investigators. The relevant criteria are:

1. Current NHLBI R35 in 6th or 7th year, or
2. Current PD/PI on at least two NHLBI R01-equivalent awards.

For the R01-equivalent route, at least one qualifying award must:

• be a single-PD/PI award,
• not be in a no-cost extension,
• and satisfy NHLBI clinical trial constraints.

The applicant must also:

• commit a minimum of 6 person-month effort equivalent throughout the OIA period,
• provide evidence of continuous NHLBI R01-equivalent support as PD/PI for the required prior-year span.

Organizational and PI configuration constraints

• Single PD/PI only. Multiple-PD/PI is not accepted.
• The organization must complete NIH-required registrations ahead of submission:
  • SAM,
  • eRA Commons,
  • Grants.gov.
• Non-US organizations are not eligible applicants.

The submission is therefore not just a science exercise; it is also a compliance exercise. If registrations are incomplete, your submission can be non-responsive even before review.

What is not eligible or is explicitly non-responsive

You can disqualify your own submission by proposing non-scope work or restricted clinical trial designs. The NOFO is explicit that:

• Research outside the NHLBI mission is non-responsive.
• NIH-defined phase I/II/III/T4 non-mechanistic trials are excluded.
• Missing institution AOR Letter of Support can make the application non-responsive.

If you want a hard filter before writing, these are the points that matter most.

Funding profile and award mechanics

This NOFO is generous relative to many standard NIH programs in terms of flexibility and duration, but not uncapped in either amount or duration.

• Up to $700,000 direct costs per year.
• Project period up to 7 years.
• NHLBI sets actual award amounts based on peer assessment, existing support, and institutional context.

The intent is to commit meaningful support to a research program, not just a single narrow piece of work. That is why budget construction must align with program architecture: if your application reads like a short pilot plan, reviewers will wonder whether this is actually an OIA fit.

Also notable:

• Up to 20 new R35 awards per year (within the broader 2026/27/28 intent envelope when paired with companion opportunity).
• Total available annual costs across this NOFO and companion line is capped by NHLBI appropriations and overall meritorious submission volume.

This creates a realistic pressure point for applicants: competitiveness is real, and budget justification needs to show both scientific reach and stewardship.

Application timeline and practical deadline strategy

Official dates from the NOFO

• Application cycle includes a February 2027 due date (plus earlier 2026 cycle).
• Expiration date shows continued time windows around this cycle.
• Review, council review, and earliest start dates are staged as standard NIH sequence.

For 2026/2027 planning:

• Build internal draft by early January 2027.
• Run at least one full compliance rehearsal before the final 5:00 PM local deadline window.
• Submit changed/ corrected versions before the deadline only; late corrected submissions are treated as late.

Practical scheduling

A stable plan should include:

• Day 1–20: final eligibility matrix and registration verification,
• Day 20–45: internal outline and narrative architecture,
• Day 45–65: first complete draft and internal review,
• Day 65+ final compliance and platform QA.

This is not a short-form R01 timeline. OIA applications must be clean on both research vision and administrative requirements.

Submission route and what to prepare

The submission systems are the standard NIH set:

• ASSIST,
• institutional S2S via Grants.gov Workspace,
• Grants.gov Workspace + eRA Commons tracking.

Required documents and form behavior

The NOFO itself is explicit: this is not where standard Specific Aims are used as usual. The OIA format requests a research strategy that presents the program direction, not a narrow single-study protocol. The practical implication is:

• Write a coherent program map.
• Show scientific productivity logic over time.
• Demonstrate why flexible long-range support is essential.

You still need to provide:

• complete institutional support letter(s),
• letters documenting current support context,
• full resource-sharing and DMS plans,
• full current and pending support details,
• all required forms and page/character limits.

Critical required evidence (usually overlooked)

Your Letter of Support from the Authorized Organizational Representative is explicitly mandatory and carries concrete content requirements. It must show:

• confirmed 6 person-month PI effort commitment,
• institutional commitment (salary, resources, protected time, space, etc.),
• explicit understanding that most NHLBI individual awards are relinquished if OIA is awarded,
• identification of the qualifying NHLBI R01-equivalent awards or R35 status.

Missing this is usually fatal.

Review logic: what reviewers actually evaluate

The OIA is reviewed as an NIH programmatic mechanism, not as a routine short project:

• Overall impact is judged on sustained scientific influence potential.
• Reviewers score significance, approach, and investigator/innovation context, but with an emphasis on:
  • proven excellence and productivity history,
  • HLBS relevance,
  • future influence and programmatic vision.

Because experimental detail is less of the core deliverable and program leadership more of a decision point, a weakly linked, fragmented portfolio narrative is often scored poorly.

In OIA review terms, a strong application shows that:

1. The investigator is clearly positioned at the top of the field,
2. The program direction is adaptable and strategically important,
3. The request is realistic relative to the proposed 7-year arc.

Common mistakes and how to avoid them

Mistake 1: Treating OIA like a standard short-cycle project grant

Applicants often submit a narrow “project + milestones only” package. OIA expects a program and portfolio logic. Rework your narrative around research trajectory, scientific leadership, and decision points.

Mistake 2: Ignoring single-PD/PI rule and parallel award interactions

If your team already has multiple-PD/PI structures or an incompatible setup in your current portfolio, you need to explain internal fit cleanly. The NOFO is strict: multiple-PD/PI applications are not accepted.

Mistake 3: Weak effort/portfolio transition plan

OIA requires 6 person-month commitment and often affects your existing NHLBI portfolio because the OIA can become your primary NIH source. Show institutional alignment and effort negotiation explicitly.

Mistake 4: Late or incomplete registrations

SAM, Commons, and Grants.gov registration is often overlooked until it is too late. The NOFO is explicit that registration delays are not excuses for non-compliance.

Mistake 5: Missing AOR letter with all required elements

The NOFO states this is not optional. A missing letter can remove applications before review.

Mistake 6: Inadequate post-award realism

Applicants understate reporting requirements. The post-award expectations (RPPR, budget reporting, DMS, data safety, clinicaltrials compliance if applicable, SAM integrity updates when required) matter. Reviewer confidence depends partly on an applicant’s ability to execute over the full award span.

Strategic blueprint if you are a candidate PI

Step 1: Verify hard eligibility

Start with a two-column matrix:

• NHLBI awards and years of continuous support,
• eligibility condition (R35 year and R01-equivalent structure).

If either side is uncertain, do not start final drafting yet.

Step 2: Draft the program narrative in layers

A strong OIA narrative has four layers:

• current scientific niche,
• five-to-seven-year program opportunities,
• risk and pivot logic,
• NHLBI mission relevance.

Reviewers expect your research program to remain within HLBS priorities while staying responsive to new opportunities over time.

Step 3: Rebuild your support evidence around continuity

Show continuity of support and output continuity (not only publication counts). Include:

• direct evidence of sustained funding and productivity,
• trajectory changes over time,
• mentoring and lab leadership scope.

Step 4: Build the budget as a program budget

Use the budget to support a stable, flexible, longer-term trajectory—not a single short experiment sequence. If you propose a broad program plan but budget only a tiny narrow effort, coherence breaks.

Step 5: Pre-submission platform dry run

Run platform checks early. The NOFO is strict about on-time and on-compliance submission behavior. Use the final week to fix warnings and route errors, not discover them at submission time.

Who should prioritize this opportunity

Good fit:

• investigators already with 2+ NHLBI R01-equivalent or R35 context,
• teams planning to scale from one lab line to a longer coherent program,
• people ready for 6+ month effort-level commitments and institutional renegotiation,
• applicants targeting high-risk, high-impact HLBS directions where current project-by-project grant cadence is too constraining.

Likely poor fit:

• teams still building foundational independence,
• early-stage R01-only programs without sustained prior NHLBI support history,
• groups with unresolved registrations or incomplete institutional administration readiness.

After submission: what happens next

The NOFO follows normal NIH flow:

• peer review by scientific review group,
• top applications receive scores and move through NHLBI advisory review,
• final award decisions include peer review strength, program balance, strategic priorities, and expected impact.

A common operational point from the NOFO is that applications outside the HLBS mission, outside scope, or non-responsive to form requirements do not enter real review.

Official links and where to verify details

• Official NOFO text: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-002.html
• NIH application guide: https://grants.nih.gov/grants/how-to-apply-application-guide
• eRA / NIH submissions support: https://www.era.nih.gov/need-help
• General NIH grants information: https://grants.nih.gov/grants/guide/
• eRA Commons: https://public.era.nih.gov/
• ClinicalTrials.gov registration (if applicable): https://www.clinicaltrials.gov/

FAQ

Is this for first-time NIH awardees?

Not usually. This is explicitly for established NHLBI-funded investigators with strong continuity and portfolio-level program maturity.

Is preliminary data mandatory?

No. The NOFO indicates preliminary data are generally not required, though they may be used where needed to justify feasibility of a new direction.

Can clinical trials be included?

Clinical trials may be included only within the NOFO’s allowed framing (e.g., mechanistic/appropriate studies). Non-mechanistic phase I/II/III/T4 trials are not allowed.

Can I hold onto other individual NHLBI grants while on OIA?

The NOFO makes clear OIA becomes the primary NHLBI individual funding source for that investigator, with defined exceptions (resources, training, certain program types, etc.). This is a major governance decision, not a peripheral administrative note.

What if deadlines are missed?

Applications have strict on-time policies and no-late correction acceptance after deadline. Internal QA and corrected-submission windows before deadline are essential.

Bottom line

If you are an established NHLBI investigator with HLBS program depth, this is a genuinely strategic 2026/2027 opportunity. The real gate is not only scientific strength, but administrative and compliance precision: single-PD/PI eligibility, AOR support quality, effort commitment, mission alignment, and complete NIH registrations.

Your best chance is to treat the OIA not as a single experiment package, but as a multi-year leadership architecture:

• a clear scientific vision,
• robust NIH readiness,
• documented continuity,
• and institutional support that can sustain seven years of high-quality research.